Anticoagulation and bleeding in the cancer patient

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Cancer patients exhibit a heightened risk of bleeding when undergoing anticoagulant therapy compared to non-cancer patients.
• Anticoagulant therapies, primarily low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs), are standard for managing cancer-associated venous thromboembolism (VTE).

Purpose of the Study:

• To highlight the increased bleeding risk in cancer patients receiving anticoagulation.
• To emphasize the importance of pre-treatment bleeding risk assessment.
• To review management strategies for major hemorrhage, including reversal agents and interventions.

Main Methods:

• Review of current literature on anticoagulation in cancer patients.
• Identification of common anticoagulant agents (LMWH, DOACs) and their use in cancer-associated VTE.
• Cataloging of available reversal agents (e.g., vitamin K, FFP, PCC, andexanet alfa, idarucizumab) and interventions (e.g., IVC filter).

Main Results:

• Cancer patients on anticoagulation have a significantly elevated risk of bleeding.
• DOACs offer convenience, but LMWH may be preferred in specific cancer types.
• Multiple reversal agents and interventions exist for managing life-threatening bleeding.

Conclusions:

• Clinical providers must be adept at identifying critical bleeding sites and employing hemorrhage reversal modalities.
• A multidisciplinary approach and shared decision-making are recommended for managing anticoagulant therapy and re-initiation after major bleeding, given sparse evidence.
• Proactive bleeding risk assessment and preparedness for hemorrhage management are essential in cancer patients receiving anticoagulation.